MARKET

ROIV

ROIV

Roivant Sciences
NASDAQ
10.66
+0.24
+2.30%
Closed 18:28 03/14 EDT
OPEN
10.52
PREV CLOSE
10.42
HIGH
10.80
LOW
10.43
VOLUME
6.25M
TURNOVER
--
52 WEEK HIGH
13.06
52 WEEK LOW
9.76
MARKET CAP
7.61B
P/E (TTM)
-77.6402
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ROIV last week (0303-0307)?
Weekly Report · 03/10 12:23
Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2024 Update
Seeking Alpha · 03/04 02:04
Genevant, Arbutus initiate patent infringement actions against Moderna
TipRanks · 03/03 14:20
GENEVANT SCIENCES AND ARBUTUS BIOPHARMA INITIATE INTERNATIONAL PATENT INFRINGEMENT ENFORCEMENT ACTIONS AGAINST MODERNA
Reuters · 03/03 14:15
GENEVANT: SEEKING MONETARY RELIEF, INJUNCTIONS AGAINST SPIKEVAX &, WHERE APPLICABLE, ADDITIONAL PRODUCTS THAT MODERNA REPRESENTED USE SAME LNP TECH
Reuters · 03/03 14:15
Weekly Report: what happened at ROIV last week (0224-0228)?
Weekly Report · 03/03 12:22
Roivant Sciences announces replacement of Arbutus Biopharma board
TipRanks · 02/25 13:31
EARLY WARNING REPORT ISSUED PURSUANT TO NATIONAL INSTRUMENT 62‐103: ROIVANT ANNOUNCES RESIGNATION AND REPLACEMENT OF ARBUTUS BOARD
Reuters · 02/25 13:00
More
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.

Webull offers Roivant Sciences Ltd stock information, including NASDAQ: ROIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ROIV stock methods without spending real money on the virtual paper trading platform.